Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers

Rhea-AI Summary

Guardant Health presented critical findings at the ESMO 2021 congress, revealing the need for improved HER2-directed therapies in metastatic colorectal cancer. Their Guardant360® liquid biopsy test highlighted treatment resistance patterns and molecular targets essential for personalized cancer care. Key studies emphasized the unmet need for effective treatments for HER2+ mCRC patients and provided insights into molecular features in early-onset colorectal cancer. The data underscores the importance of liquid biopsy in enhancing clinical outcomes for advanced cancer patients.

Positive

• Presenting new data on HER2-targeted treatments at ESMO 2021 marks a significant step in precision oncology.
• Guardant360® liquid biopsy offers valuable insights for personalizing cancer treatment.
• Research highlights the potential for improving survival rates in hard-to-treat cancers.

Negative

• Current treatment options for HER2+ metastatic colorectal cancer remain inadequate, indicating a significant unmet medical need.

GuardantINFORM™ clinical-genomic liquid biopsy dataset underscores need to improve HER-2 directed treatment in metastatic colorectal cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360^® liquid biopsy test to help improve the management of advanced solid cancers at the European Society for Medical Oncology (ESMO) 2021 virtual congress on September 16-21.

“While precision oncology has made a meaningful difference in improving clinical outcomes for highly prevalent cancers, such as non-small cell lung, colorectal, and breast, there remains a subset of patients who don’t respond to currently available treatments,” said Craig Eagle, MD, Guardant Health Chief Medical Officer. “It is gratifying to be able to work with the oncology community to analyze the molecular information generated from our liquid biopsy tests to continue to increase our understanding of possible new targets and more personalized treatments which can potentially improve overall survival of these hard-to-treat cancers in a more meaningful way.”

Guardant INFORM™ Liquid Biopsy Dataset Shows No Clear Standard of Care and Unmet Need for Patients with HER2+ Metastatic Colorectal Cancer

Title	ePoster	Presenter
Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study	439P	John Strickler

Guardant360^® Liquid Biopsy Reveals Molecular Insights Impacting Outcomes in Patients with Unresectable and Early-Onset (<50 years) Metastatic Colorectal Cancer

Title	ePoster	Presenter
Molecular features in liquid biopsy of early (EO) and late-onset colorectal cancer (LO)	500P	Julia Alcaide-Garcia
Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR)	503P	Manuel Benavides

Guardant360® Liquid Biopsy Reveals Treatment Resistance Patterns and Therapeutic Targets for the Management of Advanced Cancers Including Non-Small Cell Lung and Pancreatic

Title	ePoster	Presenter
First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA)	92P	Javier Garcia-Corbacho
Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)	1196P	Ben J. Solomon
Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer	1483P	Pedro Uson Junior

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360^®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI^® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2020 and in its other reports filed with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005307/en/

Investor Contact:

Carrie Mendivil

investors@guardanthealth.com

Media Contact:

Anna Czene

press@guardanthealth.com

Julie Johnson

julie.johnson@uncappedcommunications.com

Source: Guardant Health, Inc.

FAQ

What did Guardant Health present at ESMO 2021?

Guardant Health unveiled data regarding HER2-directed therapies and the role of Guardant360® liquid biopsy in managing metastatic colorectal cancer.

What is the focus of the GuardantINFORM™ dataset?

The dataset emphasizes the need for improved HER2-directed treatments in patients with metastatic colorectal cancer.

What are the implications of the findings for HER2+ colorectal cancer patients?

The findings highlight a significant unmet need for effective therapies, indicating that current treatments may not adequately address patient needs.

How does the Guardant360® test impact cancer treatment management?

The Guardant360® test provides molecular insights that can inform personalized treatment strategies for advanced cancers.

When was the ESMO 2021 congress held?

The ESMO 2021 congress took place from September 16-21, 2021.